The inflammatory response in sepsis.
Markus Bosmann,Peter A. Ward +1 more
Reads0
Chats0
TLDR
Recent insights into the signaling pathways in immune and phagocytic cells that underlie sepsis and SIRS are discussed and how these might be targeted for therapeutic interventions to reverse or attenuate pathways that lead to lethality during sepsi are considered.About:
This article is published in Trends in Immunology.The article was published on 2013-03-01 and is currently open access. It has received 382 citations till now. The article focuses on the topics: Systemic inflammatory response syndrome & Septic shock.read more
Citations
More filters
Journal ArticleDOI
Sepsis: a roadmap for future research
Jonathan Cohen,Jean Louis Vincent,Neill K. J. Adhikari,Flávia Ribeiro Machado,Derek C. Angus,Thierry Calandra,Katia Jaton,Stefano Giulieri,Julie Delaloye,Steven M. Opal,Kevin J. Tracey,Tom van der Poll,Eric Pelfrene +12 more
TL;DR: The understanding of the clinical epidemiology and management of sepsis is set out and how the present approaches might be challenged to develop a new roadmap for future research is asked.
Journal ArticleDOI
Sepsis: Current Dogma and New Perspectives
TL;DR: It is argued that it is time to delineate novel immunometabolic and neurophysiological mechanisms underlying the altered cellular bioenergetics and failure of epithelial and endothelial barriers that produce organ dysfunction and death.
Journal ArticleDOI
The immune system's role in sepsis progression, resolution, and long‐term outcome
Matthew J. Delano,Peter A. Ward +1 more
TL;DR: Efforts are focused on more clearly defining and effectively reversing the persistent immune cell dysfunction associated with long‐term sepsis mortality, which alters the innate and adaptive immune responses for sustained periods of time after clinical recovery.
Journal ArticleDOI
Sepsis-induced immune dysfunction: can immune therapies reduce mortality?
Matthew J. Delano,Peter A. Ward +1 more
TL;DR: These efforts are focused on defining and reversing the persistent immune cell dysfunction that is associated with mortality long after the acute events of sepsis have resolved.
Journal ArticleDOI
Complement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms
Daniel Ricklin,John D. Lambris +1 more
TL;DR: This review provides an update about the functional and collaborative capabilities of complement, highlights major disease areas with known complement contribution, and indicates the potential for complement as a focal point in immunomodulatory strategies for treating inflammatory diseases.
References
More filters
Journal ArticleDOI
Cecal ligation and puncture: the gold standard model for polymicrobial sepsis?
Lien Dejager,Iris Pinheiro,Iris Pinheiro,Eline Dejonckheere,Eline Dejonckheere,Claude Libert,Claude Libert +6 more
TL;DR: It is demonstrated that experimental sepsis models do not completely mimic human sepsi, and several therapies proposed on the basis of promising results obtained by CLP could not be translated to the clinic.
Journal ArticleDOI
The sepsis seesaw: tilting toward immunosuppression.
TL;DR: Recent human studies bolstering the notion that immunosuppression is also a major contributor to the disease are assessed.
Journal ArticleDOI
Endogenous ligands of TLR2 and TLR4: agonists or assistants?
TL;DR: The evidence supporting the intrinsic TLR‐stimulating capacity of each of these proposed endogenous ligands is summarized with a particular emphasis on the measures taken to exclude contaminating LPS and lipopeptides from experimental systems.
Journal ArticleDOI
Animal models of sepsis and sepsis-induced kidney injury
TL;DR: A bedside- to-bench-to-bedside approach that has resulted in improved animal models for the study of sepsis - a complex disease for which preventive and therapeutic strategies are unfortunately lacking.
Journal ArticleDOI
Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation
Jang Hyun Choi,Alexander S. Banks,Theodore M. Kamenecka,Scott A. Busby,Michael J. Chalmers,Naresh Kumar,Dana S. Kuruvilla,Youseung Shin,Yuanjun He,John B. Bruning,David Marciano,Michael D. Cameron,Dina Laznik,Michael J. Jurczak,Stephan C. Schürer,Dusica Vidovic,Gerald I. Shulman,Bruce M. Spiegelman,Patrick R. Griffin +18 more
TL;DR: Novel synthetic compounds are described that have a unique mode of binding to PPARγ, completely lack classical transcriptional agonism and block the Cdk5-mediated phosphorylation in cultured adipocytes and in insulin-resistant mice, and one such compound, SR1664, has potent antidiabetic activity while not causing the fluid retention and weight gain that are serious side effects of many of the PParγ drugs.
Related Papers (5)
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
Mervyn Singer,Clifford S. Deutschman,Christopher W. Seymour,Manu Shankar-Hari,Djillali Annane,Michael Bauer,Rinaldo Bellomo,Gordon R. Bernard,Jean-Daniel Chiche,Craig M. Coopersmith,Richard S. Hotchkiss,Mitchell M. Levy,John C. Marshall,Greg S. Martin,Steven M. Opal,Gordon D. Rubenfeld,Gordon D. Rubenfeld,Tom van der Poll,Jean Louis Vincent,Derek C. Angus +19 more